Xeltis

Today, Xeltis announces that the FDA has approved an Investigational Device Exemption (IDE) submission to begin enrolling patients in a pivotal study for #aXess.   This US-based pivotal trial follows strong 12-month data from a first-in-human study in Europe and marks a significant milestone in the company's clinical strategy.   aXess is a restorative conduit that allows the formation of a new living vessel for hemodialysis vascular access, providing a better dialysis patient experience. To learn more about the aXess US pivotal trial, see the press release in the comments section below. #FDA #VascularAccess #IDE

Xeltis CEO Eliane Schutte was interviewed by Optimum Strategic Communications as part of #OptimumTV.   In her conversation with Stephen Adams, Eliane discussed Xeltis' Vascular access conduit, aXess, and its potential to transform the lives of dialysis patients with end-stage kidney disease.   She highlighted the self-healing properties of Xeltis' implants and addressed the complications associated with current treatment options. Additionally, Eliane spoke about Xeltis' strategic partnerships, including with DaVita Kidney Care, and the transformative potential of #regenerative medicine in revolutionizing patient treatments and implant delivery.   Watch Eliane's episode below!

Last week, Xeltis CEO Eliane Schutte, and CMO Paulo Neves attended the 'Vascular Access Society of the Americas' 2024 Vascular Access for Hemodialysis Symposium in Atlanta, Georgia.   Reflecting on this fantastic event that united experts in vascular access, we wanted to highlight our key presentations.   CMO Paulo Neves delivered an outstanding presentation on the challenges and complexities of vascular access trials in Europe. His insights on regulatory and cost hurdles, multi-stakeholder involvement, imaging techniques, selecting the right CRO, and identifying ideal trial sites were very well received by all attendees.   They were joined by leading KOL Matteo Tozzi, who delivered an insightful presentation on Xeltis' data. His presentation was also well received by the audience, and we were grateful to have him representing Xeltis.   See both in action below!   #VASA24 #aXess #vascularaccess

Last Tuesday marked the 10th anniversary of the European Investment Bank (EIB)'s presence in the Netherlands! The jubilee event was a fantastic day filled with engaging discussions among like-minded individuals about the EIB's role in the country and its contributions to innovation. Our CFO, Alexander Goemans, participated in a panel moderated by Simone Brummelhuis from the BORSKI fund, alongside Monique Koning, Inspector General of EIB, and Manon van Beek, CEO of TenneT. Together, they explored topics such as the significance of #innovation, the mobilization of private and institutional capital, and the competitiveness of the Netherlands. Over the past decade, the EIB Group has invested over €26 billion in supporting innovation in the Netherlands, and at Xeltis we have been among the beneficiaries of this support. Back in 2021, the EIB backed #Xeltis and our mission by signing a €15 million quasi-equity financing agreement, supported by the pan-European Guarantee Fund (EGF). This funding significantly accelerated the development of Xeltis' conduits, marking a pivotal moment in our journey. We are grateful for the EIB's presence in The Netherlands and look forward to many more years. See some shots of the event below! #EIB 

Following the CX Symposium in April, Xeltis is delighted to be featured in Pharmaphorums "London’s life sciences scene upbeat as 2024 conference season begins" overview. Our CEO, Eliane Schutte, spoke with Richard Staines about the challenges facing medtech firms who have technology on trial in clinics. Read the full article below. https://lnkd.in/eUEjiUsj

Last Tuesday, our CEO Eliane Schutte took part in the Techleap Pole Position programme.   Pole Position is a joint initiative of a group of Dutch incubators – ‘Incubators United’ – and Techleap.   This programme connects founders of pre-scale deep tech with experienced entrepreneurs and scaling experts to work on challenges while developing a strong roadmap towards a global scale company.   It was great to hear from these ambitious deeptech entrepreneurs who want to make an impact like Xeltis.   #Techleap #Deeptech #Xeltis

This week, Xeltis CEO, Eliane Schutte and CMO, Paulo Neves will be attending the 'Vascular Access Society of the Americas' 2024 Vascular Access for Hemodialysis Symposium in Atlanta, Georgia. They will be joined by KOL Matteo Tozzi, MD, who will be presenting data from Xeltis' FIH #aXess trials. Our CMO Paulo Neves will be giving a presentation on the complexity of the Vascular Access trials in Europe. If you would like to join us at these presentations, see full details below: Global Dialysis Access Forum - Session 2 Title: Challenges in Setting up a Multicentre Trial in Vascular Access in Europe Speaker: Paulo Neves, MD Date: Thursday 16th May Time: 14:40 PM - 15:40 PM Session 3: Access Creation: How to Choose Title: One Year First in Human (FIH) Outcome with aXess Vascular Graft Speaker: Matteo Tozzi, MD Date: Friday 17th May Time: 11:30 AM - 12:30 PM Please get in touch if you will be attending #VASA and would like to set up a meeting! #Xeltis #VascularAccess #Hemodialysis

Today Xeltis CFO Alexander Goemans will be attending the European Investment Bank (EIB) 10 year Jubilee event in Amsterdam. Alexander will be joining Simone Brummelhuis, Borski Fund, Monique Koning, Inspector General EIB, and Manon van Beek, CEO TenneT, where they will discuss the future of innovation funding and The Netherlands as an innovation leader. #Xeltis #EIB

Today, Xeltis CEO Eliane Schutte will be attending the European Investment Bank (EIB) Venture Debt and Advisory Summit in Luxembourg.   Eliane will be joining a panel of esteemed life science leaders to discuss fundraising strategy and the importance of managing the cash runway.   To learn more about Xeltis and our transformative implants, visit our website via the link in the comments below.   #Xeltis #EIB #ADventure

Frans Moll, member of Xeltis Medical Advisory Board delivered a presentation yesterday morning at the CX Symposium. Prof Moll talked about how the transformative conduits of supramolecular polymer technology have the possibility of significantly reducing infections in multiple clinical applications. This was a great conclusion to Xeltis' time at #CX2024. If you didn't manage to meet us, please get in touch to find out more about our transformative vascular implants. #MAB #cardiovascular #aXess